FR2257288A1 - - Google Patents

Info

Publication number
FR2257288A1
FR2257288A1 FR7500543A FR7500543A FR2257288A1 FR 2257288 A1 FR2257288 A1 FR 2257288A1 FR 7500543 A FR7500543 A FR 7500543A FR 7500543 A FR7500543 A FR 7500543A FR 2257288 A1 FR2257288 A1 FR 2257288A1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7500543A
Other versions
FR2257288B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26625843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2257288(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority claimed from KR1019750000261A external-priority patent/KR800001009B1/ko
Publication of FR2257288A1 publication Critical patent/FR2257288A1/fr
Application granted granted Critical
Publication of FR2257288B1 publication Critical patent/FR2257288B1/fr
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR7500543A 1974-01-10 1975-01-09 Expired FR2257288B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US05/432,379 US4314081A (en) 1974-01-10 1974-01-10 Arloxyphenylpropylamines
KR1019750000261A KR800001009B1 (ko) 1975-01-09 1975-01-09 아릴옥시페닐프로필 아민류의 제조방법

Publications (2)

Publication Number Publication Date
FR2257288A1 true FR2257288A1 (fr) 1975-08-08
FR2257288B1 FR2257288B1 (fr) 1978-07-21

Family

ID=26625843

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7500543A Expired FR2257288B1 (fr) 1974-01-10 1975-01-09

Country Status (23)

Country Link
US (1) US4314081A (fr)
JP (1) JPS5939418B2 (fr)
AR (3) AR205578A1 (fr)
AT (1) AT336000B (fr)
BE (1) BE824255A (fr)
BG (3) BG23212A3 (fr)
CA (1) CA1051034A (fr)
CH (1) CH609675A5 (fr)
CS (1) CS189680B2 (fr)
DD (1) DD118613A5 (fr)
DE (1) DE2500110A1 (fr)
DK (1) DK140430B (fr)
ES (1) ES433720A1 (fr)
FR (1) FR2257288B1 (fr)
GB (1) GB1493961A (fr)
IE (1) IE40346B1 (fr)
NL (2) NL181654C (fr)
PH (1) PH11652A (fr)
RO (2) RO70660A (fr)
SE (1) SE412906B (fr)
SU (1) SU1005655A3 (fr)
YU (3) YU36915B (fr)
ZA (1) ZA7532B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
FR2455571A2 (fr) * 1979-02-15 1980-11-28 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre medicaments
EP1732610A2 (fr) * 2004-03-26 2006-12-20 Baylor University Inhibiteurs de reabsorption de la serotonine cibles

Families Citing this family (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584404A (en) * 1974-01-10 1986-04-22 Eli Lilly And Company Substituted phenoxyphenylproply dimethylamines
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
JPS5283811A (en) * 1976-01-01 1977-07-13 Lilly Co Eli Aryloxy phenyl propylamines and their salts
GB1570613A (en) * 1976-10-27 1980-07-02 Akzo Nv Biologically active tricyclic compounds and pharmaceutical compositions containing same
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
DE3017812A1 (de) * 1980-05-09 1981-11-12 Merck Patent Gmbh, 6100 Darmstadt Cyclopropanderivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
US4430319A (en) 1982-05-21 1984-02-07 State University Of New York Radioactive iodine labeled phenolic amines
US4692469A (en) * 1982-09-07 1987-09-08 Ciba-Geigy Corporation Propylamine derivatives
US4824868A (en) * 1982-09-07 1989-04-25 Ciba-Geigy Corporation Propylamine derivatives useful for the treatment of dementia
US4590213A (en) * 1983-04-08 1986-05-20 Eli Lilly And Company Anti-anxiety method
HU207282B (en) * 1984-05-31 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing phenyl-alkyl-amine derivatives and pharmaceutical compositions containing them
US4594358A (en) * 1985-02-25 1986-06-10 Eli Lilly And Company Analgesic method
US4683235A (en) * 1985-02-25 1987-07-28 Eli Lilly And Company Analgesic method
US4777291A (en) * 1985-02-27 1988-10-11 Eli Lilly And Company Racemization process
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5135947A (en) * 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
CA1327795C (fr) * 1987-08-14 1994-03-15 Jules Freedman Antidepresseurs de type aryloxyindanamines
US5149714A (en) * 1987-08-14 1992-09-22 Merrell Dow Pharmaceuticals Inc. Antidepressants
US4971998A (en) * 1987-10-22 1990-11-20 Massachusetts Institute Of Technology Methods for treating the premenstrual or late luteal phase syndrome
US5223540A (en) * 1987-10-22 1993-06-29 Massachusetts Institute Of Technology Method for treating the premenstrual or late luteal phase syndrome
US4996235A (en) * 1987-11-25 1991-02-26 Eli Lilly And Company 3,4-diphenylbutanamines
US4876282A (en) * 1987-11-25 1989-10-24 Eli Lilly And Company 1-Phenylalkylamines as selective serotonin uptake inhibitors
CA1337128C (fr) * 1988-04-08 1995-09-26 David Wayne Robertson Derives de propanamine
US5238959A (en) * 1988-04-08 1993-08-24 Eli Lilly And Company 3-phenyloxy-3-phenyl propanamines
US5250571A (en) * 1988-11-14 1993-10-05 Eli Lilly And Company (S)-norfluoxetine in method of inhibiting serotonin uptake
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
IT1228209B (it) * 1989-01-10 1991-06-05 Grato Magnone Procedimento per la preparazione di fluoxetina cloridrato.
US5166437A (en) * 1989-03-03 1992-11-24 Orion-Yhtyma Oy Process for the preparation of fluoxetine
FI81083C (fi) * 1989-03-03 1990-09-10 Orion Yhtymae Oy Ett foerbaettrat foerfarande foer framstaellning av n-metyl-3-(p-trifluormetylfenoxi)-3-fenylpropylamin hydroklorid.
DK258389D0 (da) * 1989-05-26 1989-05-26 Ferrosan As Aryloxyphenylpropylaminer, deres fremstilling og anvendelse
JPH0375680U (fr) * 1989-11-21 1991-07-30
US5021426A (en) * 1990-02-26 1991-06-04 Merck & Co., Inc. Method of traeting malaria with cyproheptadine derivatives
US5250572A (en) * 1990-03-29 1993-10-05 Eli Lilly And Company (R)-norfluoxetine in method for occupying serotonin IC receptors
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
PH30083A (en) * 1991-02-25 1996-12-27 Lilly Co Eli Treatment of lower urinary tract disorders
US5136079A (en) * 1991-02-26 1992-08-04 Eli Lilly And Company Regioselective synthesis
US5136078A (en) * 1991-02-26 1992-08-04 Eli Lilly And Company Synthesis of b-cyanohydrins
US5320825A (en) * 1991-05-01 1994-06-14 Trustees Of The University Of Pennsylvania Serotonin reuptake inhibitors for S.P.E.C.T. imaging
WO1993000811A1 (fr) * 1991-07-01 1993-01-21 The General Hospital Corporation Transporteur de phenylethanolamine chez les invertebres et son utilisation
IL99316A (en) 1991-08-27 1995-03-15 Teva Pharma Production of fluoxetine and new intermediates
US5202319A (en) * 1991-09-23 1993-04-13 Hoechst-Roussel Pharmaceuticals Inc. Substituted 3-amino-2,3,4,5-tetrahydro-1-aryloxy-3-benzazepines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
EP0537915B1 (fr) * 1991-09-27 1995-07-12 Eli Lilly And Company N-alkyl-3-phényl-3-(2-alkylthiophénoxy)propyl amines comme inhibiteurs de norépinéphrine
HU9202128D0 (en) * 1992-06-26 1992-10-28 Richter Gedeon Vegyeszet Method for producing n-methyl-(3-phenyl-3-(4-[trifluoro-methyl])-phenooxi-)-amine
EP0576766A1 (fr) * 1992-06-29 1994-01-05 Novo Nordisk A/S Dérivés de propanolamine, leur préparation et utilisation
US7087765B2 (en) * 1995-06-07 2006-08-08 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6017965A (en) * 1993-02-08 2000-01-25 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
CA2134038C (fr) * 1994-06-16 1997-06-03 David Taiwai Wong Potentialisation des effets de medicaments
ES2082723B1 (es) 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
EP0714663A3 (fr) 1994-11-28 1997-01-15 Lilly Co Eli Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A
US5741789A (en) 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
ES2101650B1 (es) * 1995-06-29 1998-01-16 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfenoxi) propilamina.
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
ES2101654B1 (es) * 1995-07-24 1998-01-16 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfe noxi) propilamina.
ES2101655B1 (es) * 1995-07-28 1998-01-16 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfe noxi) propilamina.
ES2103680B1 (es) * 1995-08-03 1998-04-01 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3- (p-trifluorometilfenoxi)propilamina.
ES2145977T3 (es) * 1995-08-16 2000-07-16 Lilly Co Eli Potenciacion de la respuesta de la serotonina.
ES2103681B1 (es) * 1995-09-19 1998-04-01 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil - (p-trifluorometilfenoxi) propilamina.
IT1283141B1 (it) * 1996-07-11 1998-04-07 Laporte Organics Francis S P A Procedimento per la preparazione di n-metil-3-(p-trifluorometilfenossi)-3-fenilpropilamina e dei suoi
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5830500A (en) * 1996-07-22 1998-11-03 Pentech Pharmaceuticals, Inc. Low dose fluoxetine tablet
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
PT1030667E (pt) * 1997-11-14 2005-06-30 Akzo Nobel Nv Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono
US5936124A (en) * 1998-06-22 1999-08-10 Sepacor Inc. Fluoxetine process from benzoylpropionic acid
US6025517A (en) * 1998-08-03 2000-02-15 Sepracor Inc. Fluoxetine process from benzoylacetonitrile
AU2180400A (en) * 1999-01-13 2000-08-01 Eli Lilly And Company A pharmaceutical combination for the treatment of depression
FR2791345B1 (fr) * 1999-03-26 2001-05-04 Adir Nouveaux derives du benzo[3,4]cyclobuta[1,2-c]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2000058262A1 (fr) * 1999-03-29 2000-10-05 Eli Lilly And Company Procedes stereospecifiques de preparation de la tomoxetine et de ses intermediaires
EE05315B1 (et) * 1999-09-03 2010-08-16 Eli Lilly And Company Dapoksetiini v?i selle farmatseutiliselt vastuv?etava soola kasutamine ravimi valmistamiseks, mis on ette n„htud imetajal esineva seksuaalse funktsioonih„ire ravimiseks v?i m?jutamiseks
US6677485B2 (en) 1999-12-17 2004-01-13 Ranbaxy Laboratories Limited Process for the preparation of fluoxetine hydrochloride
GB0004149D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004151D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004152D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004153D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
US6273260B1 (en) 2000-03-08 2001-08-14 Eli Lilly And Company Pharmaceutical packaging system
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
US6258853B1 (en) 2001-01-31 2001-07-10 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6310250B1 (en) 2001-01-31 2001-10-30 Grayson Walker Stowell Form A of fluoxetine hydrochloride
US6316672B1 (en) 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6313350B1 (en) 2001-01-31 2001-11-06 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6310251B1 (en) 2001-01-31 2001-10-30 Grayson Walker Stowell Form a of fluoxetine hydrochloride
JP2004525912A (ja) * 2001-03-06 2004-08-26 イーライ・リリー・アンド・カンパニー モノアミン取込の阻害剤
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
AR035700A1 (es) * 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
US7034059B2 (en) * 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
SE0102640D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
MXPA04000979A (es) * 2001-07-31 2005-02-17 Upjohn Co Tratamiento de dolor cronico con 3-ariloxi-3-fenilpropanaminas.
SE0102641D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
CA2457385A1 (fr) 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Preparation enterique de fluoxetine
US20040170688A1 (en) * 2001-08-06 2004-09-02 Deshmukh Abhijit Mukund Enteric formulation of fluoxetin
US6630454B2 (en) 2001-09-10 2003-10-07 Ramot At Tel-Aviv University Ltd. Method and pharmaceutical composition for the treatment of cancer
ES2666188T3 (es) * 2001-10-12 2018-05-03 Azevan Pharmaceuticals, Inc. Antagonistas del v1a de vasopresina beta-lactámicos
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
US20050014843A1 (en) * 2001-11-30 2005-01-20 Allen Albert John Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
NZ532065A (en) * 2001-12-11 2007-03-30 Lilly Co Eli Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US7326733B2 (en) * 2002-05-31 2008-02-05 The Forsyth Institute Methods for increasing bone density
JP2004077714A (ja) * 2002-08-15 2004-03-11 Fuji Xerox Co Ltd 光走査装置
SE0203304D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
US6846957B2 (en) * 2002-11-22 2005-01-25 Board Of Regents, The University Of Texas System Synthesis of 3-aminomethyl-1-propanol, a fluoxetine precursor
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
WO2004071431A2 (fr) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Composition et methode de traitement de troubles neurodegeneratifs
JP2006523674A (ja) * 2003-04-18 2006-10-19 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 慢性閉塞性肺疾患（ｃｏｐｄ）のための組合せ治療法
KR20110117731A (ko) * 2003-05-30 2011-10-27 랜박시 래보러터리스 리미티드 치환된 피롤 유도체와 ｈｍｇ―ｃｏ 억제제로서의 이의 용도
AU2004311577A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
US20060100290A1 (en) * 2003-07-28 2006-05-11 Dunaway Leslie J Treatment of allergic rhinitis and asthma
AU2004271800A1 (en) 2003-09-12 2005-03-24 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
ATE420881T1 (de) * 2003-09-17 2009-01-15 Janssen Pharmaceutica Nv Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors
WO2005051919A1 (fr) * 2003-11-26 2005-06-09 Pfizer Products Inc. Derives d'aminopyrazole en tant qu'inhibiteurs de la gsk-3
EP1691811B1 (fr) 2003-12-11 2014-07-23 Sunovion Pharmaceuticals Inc. Combinaison d'un sedatif et d'un modulateur des neurotransmetteurs, et methodes permettant d'ameliorer la qualite du sommeil et de traiter la depression
CA2552064A1 (fr) * 2003-12-31 2005-07-21 Actavis Group Hf Preparations d'atomoxetine
WO2006001877A2 (fr) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
EP1737473A4 (fr) * 2004-04-19 2009-08-26 Noven Therapeutics Llc Combinaisons de lithium et utilisations associees
US20050252144A1 (en) * 2004-04-29 2005-11-17 Macdonald Robert A Veneers for walls, retaining walls and the like
WO2006020850A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
WO2006020852A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006037055A1 (fr) * 2004-09-27 2006-04-06 Dr. Reddy's Laboratories Ltd. Synthese d'hydrochlorure d'atomoxetine
WO2006071868A2 (fr) * 2004-12-23 2006-07-06 Teva Pharmaceutical Industries Ltd. Processus de preparation de sels de duloxetine repondant aux normes pharmaceutiques et d'intermediaires de ceux-ci
WO2006096809A1 (fr) * 2005-03-08 2006-09-14 Teva Pharmaceutical Industries Ltd. Formes cristallines de dnt-oxalaldehyde et procedes permettant de produire des formes cristallines de dnt-oxalaldehyde
TW200639162A (en) * 2005-03-14 2006-11-16 Teva Pharma Pure duloxetine hydrochloride
EP1868434A4 (fr) 2005-03-22 2011-10-26 Azevan Pharmaceuticals Inc Acides beta-lactamylalcanoiques destines au traitement des troubles premenstruels
WO2006116151A1 (fr) 2005-04-22 2006-11-02 Wyeth Derives d’alcanamine de benzofuranyle et leurs utilisations comme agonistes 5-ht2c
TW200716583A (en) * 2005-04-22 2007-05-01 Wyeth Corp Crystal forms of {[(2R)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
AU2006239942A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
AR056980A1 (es) 2005-04-22 2007-11-07 Wyeth Corp Derivados de dihidrobenzofurano, composiciones farmaceuticas, y uso de los mismos
CN103259027A (zh) 2005-04-28 2013-08-21 普罗透斯数字保健公司 药物信息系统
US7485754B2 (en) * 2005-07-08 2009-02-03 Apotex Pharmachem Inc. Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers
CA2614289A1 (fr) * 2005-07-08 2007-01-18 Braincells, Inc. Methodes destinees a identifier des agents et des conditions modulant la neurogenese
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
KR101523776B1 (ko) 2005-07-19 2015-05-28 아제반 파마슈티칼스, 인코퍼레이티드 베타-락타민 페닐알라닌, 시스테인 그리고 세린 바소프레신길항물질
CA2615063A1 (fr) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. Formes posologiques et preparations a charge medicamenteuse elevee
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
WO2007038253A2 (fr) * 2005-09-22 2007-04-05 Teva Pharmaceutical Industries Ltd. Dnt-maleate, procedes de preparation de dernier
US20080207923A1 (en) * 2005-09-22 2008-08-28 Santiago Ini Pure DNT-maleate and methods of preparation thereof
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
AU2006313430B2 (en) * 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
CN1304360C (zh) * 2005-12-12 2007-03-14 天津大学 N,n－二甲基－3－羟基－3－芳基丙胺的制备方法
US20070191471A1 (en) * 2006-01-23 2007-08-16 Santiago Ini DNT-fumarate and methods of preparation thereof
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
WO2007104035A1 (fr) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation de neurogenèse par des agents nootropes
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2008020314A2 (fr) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Formulations de dosage stabilisantes à base de statine
CN101410112A (zh) * 2006-03-24 2009-04-15 惠氏公司 治疗抑郁症的新治疗组合
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
MX2008001079A (es) * 2006-05-23 2008-03-19 Teva Pharma Polimorfos de hidrocloruro de duloxetina.
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
WO2008010087A2 (fr) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited FORMES POLYMORPHES D'UN INHIBITEUR DE LA HMG-CoA-RÉDUCTASE ET LEURS UTILISATIONS
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
WO2008026227A2 (fr) * 2006-08-28 2008-03-06 Matrix Laboratories Ltd Procédé de préparation de chlorhydrate d'atomoxétine
EP2068872A1 (fr) * 2006-09-08 2009-06-17 Braincells, Inc. Combinaisons contenant un dérivé de 4-acylaminopyridine
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
KR20090071598A (ko) 2006-09-18 2009-07-01 랩터 파마슈티컬 인코포레이티드 수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
ITMI20061987A1 (it) 2006-10-16 2008-04-17 Archimica Srl Processo per la sintesi di arilossipropilammine ed eteroarilossipropilammine.
WO2008062473A1 (fr) * 2006-10-31 2008-05-29 Cadila Healthcare Limited Procédé de préparation de chlorhydrate d'atomoxétine
FR2910319B1 (fr) 2006-12-20 2011-06-03 Substipharm Dev Formulations pharmaceutiques dispersibles contenant de la fluoxetine
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
EP2125017A2 (fr) * 2007-01-11 2009-12-02 Braincells, Inc. Modulation de la neurogenèse en utilisant du modafinil
WO2008122019A1 (fr) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Amélioration de la tolérabilité de la mirtazapine et de la réboxétine par leur utilisation en combinaison
US20090137598A1 (en) 2007-06-21 2009-05-28 Veroscience, Llc Method of treating metabolic disorders and depression with dopamine receptor agonists
WO2009141833A2 (fr) * 2008-04-17 2009-11-26 Ind-Swift Laboratories Limited Procédé amélioré pour synthétiser de l'atomoxétine extrêmement pure
WO2009128058A1 (fr) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Produits psycho-pharmaceutiques
PT2398500T (pt) 2009-02-20 2019-06-14 2 Bbb Medicines B V Sistema de entrega de medicamentos à base de glutationas
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
TWI556839B (zh) 2009-05-06 2016-11-11 研究室護膚股份有限公司 包含活性劑－磷酸鈣粒子複合物之皮膚遞送組成物及其使用方法
WO2011027359A2 (fr) 2009-07-30 2011-03-10 Matrix Laboratories Ltd Nouveau procédé de préparation de 4-hydroxy atomoxétine
EP2348120B1 (fr) 2009-12-30 2014-06-11 Universität Wien Réduction enzymatique de 1-phénylpropanone et dérivés associés
PL2587919T3 (pl) 2010-07-01 2018-05-30 Azevan Pharmaceuticals, Inc. Sposoby leczenia zespołu stresu pourazowego
WO2012020418A1 (fr) 2010-08-12 2012-02-16 Matrix Laboratories Ltd Nouveaux polymorphes de chlorhydrate de 4-hydroxy-atomoxétine
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
EP2685966A1 (fr) 2011-03-17 2014-01-22 Lupin Limited Compositions pharmaceutiques à libération contrôlée d'un inhibiteur sélectif de la recapture de sérotonine
EP2879517A1 (fr) 2012-07-31 2015-06-10 Sanovel Hayvan Sagligi Ürünleri Sanayi ve Ticaret A.S. Utilisation de fluoxétine pour augmenter la production de viande et de lait
WO2014021801A1 (fr) 2012-07-31 2014-02-06 Sanovel Hayvan Sagligi Ürünleri Sanayi Ve Ticaret A.S. Utilisation de fluoxétine chez des animaux
WO2014046544A1 (fr) 2012-09-21 2014-03-27 Aapa B.V. 3-hétéroaryloxy-3-(hétéro)aryl-propylamines substituées comme modulateurs de transporteur de la sérotonine et du récepteur ht2c de la sérotonine
NZ724718A (en) 2014-03-28 2023-04-28 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
CN105777706B (zh) * 2014-12-25 2019-08-23 江苏恩华药业股份有限公司 一种3-[(苯并[d][1, 3]二氧戊环-4-基)-氧基]-3-芳基丙胺类化合物及其应用
CA3075759A1 (fr) 2017-09-15 2019-03-21 Azevan Pharmaceuticals, Inc. Compositions et procedes pour le traitement d'une lesion cerebrale
WO2021016112A2 (fr) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Régimes de traitement non sédatifs à base de dexmédétomidine
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2683742A (en) * 1951-02-23 1954-07-13 Searle & Co Nu, nu-disubstituted omega-arylmethoxy-omega-arylalkylamine derivatives
ES251290A1 (es) * 1958-08-21 1960-04-01 Parke Davis & Co Un procedimiento para la producciën de alcohilaminas arilsustituidas
US3132179A (en) * 1959-08-27 1964-05-05 Sterling Drug Inc Ethers of alpha-hydroxymethyl-beta-monocarbocyclic aryl ethyl amines and their preparation
US3253040A (en) * 1962-12-10 1966-05-24 Union Carbide Corp Process for the production of primary 3-hydrocarbyloxypropylamines

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
FR2455571A2 (fr) * 1979-02-15 1980-11-28 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre medicaments
EP1732610A2 (fr) * 2004-03-26 2006-12-20 Baylor University Inhibiteurs de reabsorption de la serotonine cibles

Also Published As

Publication number Publication date
GB1493961A (en) 1977-12-07
NL930108I2 (nl) 1994-08-16
BG23212A3 (bg) 1977-07-12
US4314081A (en) 1982-02-02
DK140430C (fr) 1980-01-21
NL181654B (nl) 1987-05-04
FR2257288B1 (fr) 1978-07-21
DK140430B (da) 1979-08-27
ES433720A1 (es) 1976-12-01
NL930108I1 (nl) 1993-10-18
SE412906B (sv) 1980-03-24
YU37307B (en) 1984-08-31
YU121581A (en) 1983-04-27
SU1005655A3 (ru) 1983-03-15
JPS50101333A (fr) 1975-08-11
ATA10275A (de) 1976-08-15
BG26192A3 (bg) 1979-02-15
BG60761B2 (bg) 1996-02-29
RO70660A (fr) 1983-09-26
IE40346L (en) 1975-07-10
JPS5939418B2 (ja) 1984-09-22
CS189680B2 (en) 1979-04-30
AR205577A1 (es) 1976-05-14
AR205578A1 (es) 1976-05-14
DD118613A5 (fr) 1976-03-12
YU37308B (en) 1984-08-31
ZA7532B (en) 1976-08-25
IE40346B1 (en) 1979-05-09
SE7500215L (fr) 1975-07-11
PH11652A (en) 1978-05-08
DE2500110C2 (fr) 1987-06-11
CH609675A5 (fr) 1979-03-15
AT336000B (de) 1977-04-12
AU7683674A (en) 1976-06-24
NL181654C (nl) 1987-10-01
CA1051034A (fr) 1979-03-20
RO70660B (ro) 1983-08-30
NL7500186A (nl) 1975-07-14
YU121481A (en) 1983-04-27
YU36915B (en) 1984-08-31
DK688974A (fr) 1975-09-01
DE2500110A1 (de) 1975-07-17
AR205633A1 (es) 1976-05-21
RO69763A (fr) 1982-02-26
BE824255A (fr) 1975-07-09
YU3275A (en) 1982-06-18

Similar Documents

Publication Publication Date Title
FR2257288B1 (fr)
AU495930B2 (fr)
JPS50103744A (fr)
IN144462B (fr)
DK656174A (fr)
CS166386B1 (fr)
CH568539A5 (fr)
BG21351A1 (fr)
BG21307A1 (fr)
BG21129A1 (fr)
BG22114A1 (fr)
BG22156A1 (fr)
BG22571A1 (fr)
CH569220A5 (fr)
BG22586A1 (fr)
BG22624A1 (fr)
BG20950A1 (fr)
BG22709A1 (fr)
BG21352A1 (fr)
BG20883A1 (fr)
BG23065A1 (fr)
BG22040A1 (fr)
CH1163975A4 (fr)
BG22061A3 (fr)
BG19768A1 (fr)

Legal Events

Date Code Title Description
CC Supplementary protection certificate (spc) laid open to the public (law of 25 june 1990)

Free format text: 91C0006, 911230

CB Supplementary protection certificate (spc) granted (law of 25 june 1990)

Free format text: 91C0006, 750109

CP Supplementary protection certificate (spc) filed
CL Concession to grant licences